Search

FDA Clears Concerto Biosciences’ IND for Live Biotherapeutic Product to Treat AD

The U.S. Food and Drug Administration (FDA) has cleared Concerto Biosciences’ Investigational New Drug (IND) application to initiate a Phase 1, first-in-human trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product (LBP) to treat atopic dermatitis (AD). The company discovered ENS-002 with kChip, its proprietary screening technology for identifying microbial, prebiotic, and postbiotic product candidates. […]